アログリプチン錠特定薬剤使用調査「血糖降下薬（例：インスリン製剤または速効型インスリン分泌促進薬）との併用療法を受けている2型糖尿病患者」

基本情報

NCT ID

NCT02221284

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

964

治験依頼者名

Takeda

概要

The purpose of this survey is to evaluate the safety and efficacy of long-term use of alogliptin tablets (Nesina Tablets) in type 2 diabetic patients who have had an inadequate response to hypoglycemic agents (e.g., insulin preparations or rapid-acting insulin secretagogues)\* in addition to dietary/exercise therapy. Participants will receive alogliptin as part of routine medical care. \* Patients receiving these hypoglycemic agents (excluding α-glucosidase inhibitors, thiazolidines, sulfonylureas, and biguanides) were excluded from existing specified drug-use surveys for alogliptin tablets.

対象疾患

介入

依頼者（Sponsor）